Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ANX007 in Dry Age-Related Macular Degeneration with Geographic Atrophy
2024-515022-88-00Phase 3Authorised
- Sponsor
- Annexon Biosciences
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of vonaprument in geographic atrophy (GA) (2 arms), sponsored by Annexon Biosciences. Primary endpoint: Confirmed BCVA ≥15-letter loss from baseline through Month 15. Planned start Feb 2025; status: authorised.
02
Drugs
vonaprument
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on 2024-515022-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515022-88-00.